The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension
نویسندگان
چکیده
منابع مشابه
Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Pulmonary arterial hypertension (PAH) is a rare disease characterized by vascular proliferation and remodeling, resulting in a progressive increase in pulmonary arterial resistance, right heart failure, and death. The pathogenesis of PAH is multifactorial, with endothelial cell dysfunction playing an integral role. This endothelial dysfunction is characterized by an overproduction of vasoconstr...
متن کاملPhosphodiesterase Type 5 Inhibitors for Pulmonary Arterial Hypertension
n engl j med 361;19 nejm.org november 5, 2009 1864 This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies, the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines, if they exist, are prese...
متن کاملCombination therapy with bosentan and phosphodiesterase-5 inhibitor in pulmonary arterial hypertension.
therapy to control lung damage in patients with common variable immunodeficiency. Int Immunopharmacol 2004; 6: 745–753. 4 de Gracia J, Morell F, Bofill JM, Rodrigo MJ, Cosculluela C. Impaired lung function in patients with IgA deficiency and low levels of IgG2 or IgG3. N Engl J Med 1986; 314: 925–926. 5 de Gracia J, Miravitlles M, Vendrell M, Rodrigo MJ, Codina R, Morell F. Study of the IgG sub...
متن کاملDual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study
BACKGROUND Recent vasodilating drugs have improved prognosis of Pulmonary arterial hypertension (PAH). Some reports describe the merits of combination therapies for PAH, and this study evaluated the efficacy and safety of phosphodiesterase type 5 inhibitors (PDE5i) combination therapy, using sildenafil and tadalafil, for multi-drug-resistant PAH. METHODS We retrospectively analyzed 7 consecut...
متن کاملThe Phosphodiesterase-5 Inhibitor Vardenafil Is a Potent Inhibitor of ABCB1/P-Glycoprotein Transporter
One of the major causes of chemotherapy failure in cancer treatment is multidrug resistance (MDR) which is mediated by the ABCB1/P-glycoprotein. Previously, through the use of an extensive screening process, we found that vardenafil, a phosphodiesterase 5 (PDE-5) inhibitor significantly reverses MDR in ABCB1 overexpressing cancer cells, and its efficacy was greater than that of tadalafil, anoth...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cardiovascular Research
سال: 2013
ISSN: 1755-3245,0008-6363
DOI: 10.1093/cvr/cvt109